Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACHROMYCIN V vs ACTISITE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-t RNA binding to m RNA-ribosome complex.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.
Infections caused by susceptible strains of bacteria including rickettsiae, Mycoplasma pneumoniae, Chlamydia trachomatis, and spirochetes,Acne vulgaris,Adjunctive therapy in severe acne,Off-label: Chronic prostatitis, sclerosing keratitis, rosacea
Treatment of periodontal disease (adjunct to scaling and root planing),Topical treatment of infected wounds and skin ulcers
250-500 mg orally every 6 hours
Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.
Terminal elimination half-life is 6-12 hours in patients with normal renal function; prolonged in renal impairment (up to 48-72 hours in anuria).
Not applicable due to local degradation; systemic half-life is negligible as tetracycline hydrochloride is not absorbed.
Not extensively metabolized; primarily excreted unchanged in urine via glomerular filtration; small amount metabolized in liver.
Not significantly metabolized; primarily excreted unchanged in urine and feces.
Renal (60% unchanged in urine via glomerular filtration), biliary/fecal (40% as active drug and metabolites, with a portion undergoing enterohepatic recirculation).
Primarily eliminated by phagocytic degradation at the application site; minimal systemic absorption, negligible renal or biliary excretion.
50-65% bound to serum albumin; primarily binds to alpha-1-acid glycoprotein.
Not applicable (no systemic absorption); if systemically present, tetracycline is 50-60% bound to plasma proteins.
1.5-2.0 L/kg (large volume indicates extensive tissue distribution, concentrating in bile, liver, kidneys, and bone; minimal CNS penetration despite lipophilicity).
Not applicable due to lack of systemic absorption; if systemic, tetracycline Vd is 1.3-1.6 L/kg.
Oral: 60-80% (reduced by food, particularly dairy products, due to chelation with divalent cations). Intravenous: 100%.
Negligible systemic bioavailability (<0.1%) when applied topically; not administered orally or intravenously for periodontal use.
GFR 50-80 m L/min: no adjustment; GFR 10-50 m L/min: 250-500 mg every 12-24 hours; GFR <10 m L/min: 250-500 mg every 24 hours
Not systemically absorbed; no renal adjustment required.
No dosage adjustment required; use with caution in severe hepatic impairment due to potential hepatotoxicity
Not systemically absorbed; no hepatic adjustment required.
Children >8 years: 25-50 mg/kg/day orally divided every 6 hours
Safety and efficacy not established in pediatric patients.
Consider age-related renal impairment; adjust dose based on GFR; avoid if possible due to increased risk of photosensitivity and gastrointestinal effects
No specific dose adjustment; use standard adult dosing with caution for age-related comorbidities.
Use during tooth development (last half of pregnancy, infancy, childhood to age 8 years) may cause permanent discoloration of teeth (yellow-gray-brown).
None
Photosensitivity manifested by exaggerated sunburn reaction,Renal impairment may lead to drug accumulation and potential hepatotoxicity,Superinfection with resistant organisms including fungi,Bone growth retardation in premature infants,Pseudotumor cerebri (benign intracranial hypertension) in adults
Photosensitivity,Superinfection with resistant organisms,Use in renal impairment may require dose adjustment,Not recommended in children under 8 years due to permanent tooth discoloration
Hypersensitivity to tetracyclines,Pregnancy,Children under 8 years of age,Severe renal or hepatic impairment
Hypersensitivity to tetracyclines,Severe renal impairment
Avoid dairy products (milk, cheese, yogurt) and calcium-fortified foods within 2-4 hours of dosing. Also avoid concurrent intake of iron-rich foods or supplements, zinc, magnesium, and antacids. High-fat meals may reduce absorption; take on an empty stomach.
No direct food interactions. Avoid eating on the treated side to prevent dislodgement of the fiber. Maintain soft diet to minimize trauma. Avoid alcohol-based mouthwashes.
Tetracyclines, including ACHROMYCIN V (tetracycline hydrochloride), are classified as FDA Pregnancy Category D. Use during the second and third trimesters may cause permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus. Reversible inhibition of bone growth has been reported. First-trimester exposure is associated with a small risk of neural tube defects and other malformations in some studies. Avoid use during pregnancy unless for serious infections (e.g., anthrax, brucellosis) when alternative antibiotics are contraindicated.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, tetracycline hydrochloride (active component) caused fetal toxicity (skeletal malformations, reduced fetal weight) at doses 1-2 times the human dose. First trimester: potential for teratogenicity (neural tube defects, cardiovascular anomalies). Second and third trimesters: risk of permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus; also potential for inhibition of fetal bone growth and maternal hepatotoxicity. Use only if potential benefit outweighs risk.
Tetracycline is excreted into human milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.6–0.8. Theoretical risks include dental staining and bone growth inhibition in the nursing infant. Short-term use at recommended doses is generally considered compatible with breastfeeding by the American Academy of Pediatrics, but prolonged or repeated courses should be avoided. Monitor infant for potential gastrointestinal disturbances or rash.
Tetracycline is excreted in human milk (M/P ratio approximately 0.6-1.5). Due to potential for serious adverse reactions (tooth discoloration, bone growth inhibition, photosensitivity) in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Avoid prolonged use during breastfeeding.
Pregnancy reduces tetracycline serum concentrations due to increased volume of distribution and enhanced hepatic clearance. However, dose adjustments are not routinely recommended because the drug is generally avoided in pregnancy. If use is unavoidable (e.g., anthrax), standard adult doses (e.g., 250-500 mg every 6 hours) may be insufficient; consider monitoring serum levels if available and adjusting based on clinical response. Avoid in the second and third trimesters if possible.
No specific dose adjustments for ACTISITE (tetracycline periodontal fiber). Systemic absorption minimal (peak serum concentrations <0.1 mcg/m L). Pregnancy may alter pharmacokinetics of tetracycline (increased volume of distribution, decreased protein binding), but due to local administration, systemic effects are negligible. No dosage adjustment required for the fiber formulation; however, avoid systemic tetracycline use during pregnancy when possible.
Tetracycline chelates with divalent and trivalent cations; avoid concurrent administration with dairy, antacids, iron, or calcium supplements. Photosensitivity risk: advise sun avoidance and use of sunscreen. Monitor renal function in elderly; adjust dose in severe renal impairment. Not for use in pregnancy or children under 8 years due to tooth discoloration and bone growth inhibition. Administer on an empty stomach (1 hour before or 2 hours after meals) for optimal absorption.
ACTISITE (tetracycline hydrochloride) periodontal fiber is a controlled-release local antibiotic for adjunctive treatment of chronic periodontitis. Insert fiber into periodontal pocket to deliver drug over 10 days. Ensure pocket depth is ≥5mm. Do not use with metallic or synthetic fibers. Fiber must be secured with cyanoacrylate adhesive. Monitor for foreign body sensation, pain, or infection. Removal at 10 days is mandatory to avoid excessive tissue reaction. Not for acute abscesses.
Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals.,Avoid dairy products, antacids, iron supplements, and calcium supplements within 2-4 hours of taking this drug.,Protect your skin from sun exposure; use sunscreen and wear protective clothing as this medicine can cause severe sunburn.,Do not take this drug if you are pregnant or breastfeeding; it can harm the baby's teeth and bones.,Complete the full course of treatment even if you feel better; do not skip doses.,Report any signs of allergic reaction, severe headache, blurred vision, or persistent diarrhea to your doctor immediately.,Store at room temperature away from moisture and light.
Do not brush or floss the treated area while the fiber is in place.,Avoid chewing hard or sticky foods on the treated side.,You may feel a mild foreign body sensation; report severe pain or swelling.,The fiber must be removed after 10 days; do not leave it longer.,Complete the full course of prescribed oral hygiene and antibiotics if given.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACHROMYCIN V vs ACTISITE, answered by our medical review team.
ACHROMYCIN V is a Tetracycline Antibiotic that works by Bacteriostatic; binds reversibly to 30S ribosomal subunit, inhibits protein synthesis by blocking aminoacyl-t RNA binding to m RNA-ribosome complex.. ACTISITE is a Tetracycline Antibiotic that works by Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACHROMYCIN V and ACTISITE depend on the specific clinical indication. These are both Tetracycline Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACHROMYCIN V is: 250-500 mg orally every 6 hours. The standard adult dose of ACTISITE is: Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACHROMYCIN V and ACTISITE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACHROMYCIN V is classified as Category C. Tetracyclines, including ACHROMYCIN V (tetracycline hydrochloride), are classified as FDA Pregnancy Category D. Use during the second and third trimesters may cause permanent tooth. ACTISITE is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, tetracycline hydrochloride (active component) caused fetal toxicity (skeletal malformations, red. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.